Clinical trialNCT05703971RecruitingPhase 1/PHASE2Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

SponsorGenprex, Inc.Enrollment62Small Cell Lung Cancer Extensive Stage

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark S Berger, MD
Genprex, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rocky Mountain Cancer Centers, Llp
Lone Tree, Colorado, United States
Robert M Jotte, MD
Recruiting
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
Daniel Morgensztern, MD
Recruiting
Gabrail Cancer Center Research
Canton, Ohio, United States
Nashat Gabrail, MD
Recruiting
Oncology_hematology Care Clinical Trials, Llc
Cincinnati, Ohio, United States
David M Waterhouse, MD
Recruiting
Oncology_hematology Care Clinical Trials, Llc
Cincinnati, Ohio, United States
David M Waterhouse, MD
Recruiting
Oncology_hematology Care Clinical Trials, Llc
Cincinnati, Ohio, United States
David M Waterhouse, MD
Recruiting
Oncology_hematology Care Clinical Trials, Llc
Cincinnati, Ohio, United States
David M Waterhouse, MD
Recruiting
Oncology_hematology Care Clinical Trials, Llc
Fairfield, Ohio, United States
David M Waterhouse, MD
Recruiting
Willamette Valley Cancer Institute (oregon)
Eugene, Oregon, United States
Bo Wang, MD
Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States
Anthony Van Ho, MD
Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States
Anthony Van Ho, MD
Recruiting
Providence Cancer Institute
Portland, Oregon, United States
Rachel Sanborn, MD
Recruiting
Northwest Cancer Specialists, P.C.
Tigard, Oregon, United States
Anthony Van Ho, MD
Recruiting
Texas Oncology - Dfw
Dallas, Texas, United States
Kartik Konduri, MD
Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas, United States
Donald A Richards, MD
Recruiting
Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States
Alexander I Spira, MD
Recruiting
Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States
Terminated

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Quaratusugene ozeplasmid →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 May 2024
Primary completion: 30 Jun 2026
Completion: 31 Aug 2027
Last update posted: 3 Jun 2026
Registered enrollment: 62
Registry id: NCT05703971

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.